Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24146230 | 1.00 | CYP1A2 (0.44) | CYP1A2CHRM5ADRA2CACHESIGMAR1 | |
| SCHEMBL11850078 | 0.88 | CYP1A2 (0.48) | CYP1A2CHRM5ADRA2CACHESIGMAR1 | |
| SCHEMBL3218288 | 0.86 | CHRM5 (0.58) | CYP1A2CHRM5ADRA2CSIGMAR1CHRM3 | |
| SCHEMBL12945 | 0.86 | CHRM5 (0.58) | CYP1A2CHRM5ADRA2CSIGMAR1CHRM3 | |
| SCHEMBL30340999 | 0.86 | CHRM5 (0.58) | CYP1A2CHRM5ADRA2CSIGMAR1CHRM3 | |
| SCHEMBL24146232 | 0.84 | CYP1A2 (0.42) | CYP1A2CHRM5ADRA2CACHESIGMAR1 | |
| SCHEMBL10949210 | 0.83 | CHRM5 (0.54) | CYP1A2CHRM5ADRA2CSIGMAR1CHRM3 | |
| SCHEMBL24008480 | 0.83 | KCNA3 (0.43) | CYP1A2CHRM5ADRA2CACHESIGMAR1 | |
| SCHEMBL17828184 | 0.83 | ACHE (0.64) | CYP1A2CHRM5ADRA2CACHESIGMAR1 | |
| SCHEMBL10261041 | 0.80 | CYP1A2 (0.47) | CYP1A2CHRM5ADRA2CACHESIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158157-A1 | POTENT AND SELECTIVE DEGRADERS OF ALK | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158157-A1 | POTENT AND SELECTIVE DEGRADERS OF ALK | ALK, ERBB2, PDGFRB | CYP1A2 3390/4885CHRM5 4230/4885ADRA2C 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.